VNRX 株価推移チャート
VNRX 収入
VolitionRX Ltd
$0.14
-8.68%
$-0.01
終値： Apr 23, 16:00:00 GMT-4
$0.14
-1.45%
$0
アフターマーケット：Apr 23, 19:16:56 GMT-4
戻る
VolitionRX Ltd (VNRX) 収入
主要データ
前終値
$0.1577
始値
$0.1571
当日レンジ
$0.14 - $0.1571
52週レンジ
$0.1419 - $0.94
取引高
3.8M
平均取引高
8.4M
配当利回り
--
1株当たり利益(TTM)
-0.22
時価総額
$22.4M
VNRXとは何ですか？
VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. The company is headquartered in Henderson, Nevada and currently employs 85 full-time employees. The company went IPO on 2015-02-06. The firm is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.